• Genervon Biopharmaceuticals LLC, of Pasadena, Calif., said it received FDA approval for an amyotrophic lateral sclerosis (ALS) Phase IIa trial for GM604, which has been found to modulate more than 80 ALS-related gene targets (efficacy and target biomarkers) interactively and dynamically, through up to 12 pathways and 22 biological processes. Patient recruitment for the trial has started.